Diginex Limited (NASDAQ:DGNX – Get Free Report) shares fell 12.3% on Wednesday . The company traded as low as $19.39 and last traded at $20.43. 1,004,711 shares were traded during mid-day trading, a decline of 1% from the average session volume of 1,011,411 shares. The stock had previously closed at $23.30.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Diginex in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.
Read Our Latest Stock Analysis on DGNX
Diginex Trading Down 12.3%
Institutional Investors Weigh In On Diginex
A hedge fund recently raised its stake in Diginex stock. Geode Capital Management LLC lifted its holdings in Diginex Limited (NASDAQ:DGNX – Free Report) by 10.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,315 shares of the company’s stock after buying an additional 1,748 shares during the quarter. Geode Capital Management LLC owned approximately 0.08% of Diginex worth $994,000 at the end of the most recent quarter.
About Diginex
DSL is the wholly owned subsidiary of Diginex Limited. Accordingly, Diginex Limited owns 100% of DSL and all of DSL’s business lines and subsidiaries. DSL is an impact technology business that helps organizations to address the some of the most pressing Environmental, Social and Governance (“ESG”), climate and sustainability issues, utilizing blockchain, machine learning and data analysis technology to lead change and increase transparency in corporate social responsibility and climate action.
Featured Articles
- Five stocks we like better than Diginex
- What Are Dividend Champions? How to Invest in the Champions
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Options Trading – Understanding Strike Price
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Diginex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diginex and related companies with MarketBeat.com's FREE daily email newsletter.